Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
AMBIT BIOSCIENCES CORP (AMBI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/12/2014 8-K Quarterly results
Docs: "AMBIT BIOSCIENCES ANNOUNCES SECOND QUARTER 2014 OPERATING RESULTS SAN DIEGO — August 12, 2014 — Ambit Biosciences , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the second quarter 2014. The company will host a conference call today to discuss financial results for the quarter and to provide an operational update for the first half of 2014. “We are pleased to have initiated our QUANTUM-R Phase 3 trial, our most notable achievement of the first half,” said Michael Martino, Ambit's President and Chief Executive Officer. “The trial is progressing and sites continue to be activated on plan. This will remain our primary operating focus throughout the year. We..."
05/06/2014 8-K Quarterly results
Docs: "AMBIT BIOSCIENCES ANNOUNCES FIRST QUARTER 2014 OPERATING RESULTS"
11/07/2013 8-K Quarterly results
Docs: "AMBIT BIOSCIENCES ANNOUNCES THIRD QUARTER 2013 OPERATING RESULTS"
08/13/2013 8-K Quarterly results
Docs: "Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results - Company to Host Conference Call and Webcast at 5:00 p.m. EDT, Today, August 13, 2013 SAN DIEGO - August 13, 2013 - Ambit Biosciences , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced results for the second quarter and six months ended June 30, 2013. The company will host a conference call today to provide an operational update and discuss financial results, its first as a public company. “The second quarter was transformative for Ambit. We successfully completed our initial public offering, which put us on solid financial footing to continue the clinical development of quizartinib, our lead drug c..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy